Table 3.

Risk of SPC by lung cancer histology after BC diagnosis (1993–2013)

	Latency (months)
	Total		< 12	12–59	60–119	≥120
	SIR (O/E)	95% CI	SIR (O/E)	SIR (O/E)	SIR (O/E)	SIR (O/E)
Lung, bronchus	1.05 (782/748.26)	(0.97–1.12)	0.98 (90/91.90)	1.07 (331/309.19)	1.03 (227/220.22)	1.06 (134/126.96)
Squamous cell carcinoma	1.15# (280/243.85)	(1.02–1.29)	0.94 (29/30.71)	1.18 (121/102.47)	1.08 (77/71.04)	1.34# (53/39.63)
Adenocarcinoma	1.20# (221/183.65)	(1.05–1.37)	1.39 (30/21.61)	1.27# (94/74.26)	1.15 (63/54.55)	1.02 (34/33.23)
Small cell carcinoma	1.06 (99/93.82)	(0.86–1.28)	0.69 (8/11.64)	1.10 (43/39.13)	1.13 (31/27.46)	1.09 (17/15.58)
Other and unspecified	0.80# (182/226.95)	(0.69–0.93)	0.82 (23/27.95)	0.78# (73/93.32)	0.83 (56/67.16)	0.78 (30/38.51)

SPC: second primary cancer, BC: bladder cancer, SIR: standardized incidence ratio, CI: confidence interval, O/E: Observed/Expected

# significant at alpha = 0.05